anti-CD123/anti-CD16A bispecific antibody AFM28
Term · Oncology and biomedicine · MLC-T-ONC-010219
A human, tetravalent, bispecific immunoglobulin G1 (IgG1)-single chain variable fragment (scFv) fusion antibody targeting both the tumor-associated antigen (TAA) CD123 and the human low affinity immunoglobulin G (IgG) Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD123/CD16A bispecific antibody AFM28 simultaneously targets and binds to CD16A expressed on natural killer (NK) cells and macrophages, and to CD123 on CD123-expressing tumor cells, thereby selectively cross-linking CD123-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, induce antibody-dependent cellular cytotoxicity (ADCC), and eventually causes tumor cell lysis. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. CD16A is specifically expressed on the surface of NK cells and macrophages.
| Identifier | MLC-T-ONC-010219 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | bispecific innate cell engager AFM28; ICE AFM28; bispecific antibody anti-CD123/anti-CD16A AFM28 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010219",
"term": "anti-CD123/anti-CD16A bispecific antibody AFM28",
"field": "Oncology and biomedicine",
"definition": "A human, tetravalent, bispecific immunoglobulin G1 (IgG1)-single chain variable fragment (scFv) fusion antibody targeting both the tumor-associated antigen (TAA) CD123 and the human low affinity immunoglobulin G (IgG) Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD123/CD16A bispecific antibody AFM28 simultaneously targets and binds to CD16A expressed on natural killer (NK) cells and macrophages, and to CD123 on CD123-expressing tumor cells, thereby selectively cross-linking CD123-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, induce antibody-dependent cellular cytotoxicity (ADCC), and eventually causes tumor cell lysis. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. CD16A is specifically expressed on the surface of NK cells and macrophages.",
"synonyms": [
"bispecific innate cell engager AFM28",
"ICE AFM28",
"bispecific antibody anti-CD123/anti-CD16A AFM28"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd123-anti-cd16a-bispecific-antibody-afm28/"
}
Record 1,304 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.